
GT Biopharma GTBP
$ 0.39
-2.18%
Annual report 2025
added 03-02-2026
GT Biopharma Long Term Debt Current 2011-2026 | GTBP
Annual Long Term Debt Current GT Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 58 K | 110 K | - | - | 120 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 120 K | 58 K | 96 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 4.34 | 9.32 % | $ 10.4 B | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Aligos Therapeutics
ALGS
|
3.58 M | $ 6.61 | -13.71 % | $ 65.3 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 310.78 | -2.92 % | $ 40.7 B | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 22.7 | 4.08 % | $ 1.06 B | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 104.52 | 2.35 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.04 | -1.3 % | $ 5 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
65 K | $ 1.18 | 9.81 % | $ 14.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.44 | 6.67 % | $ 370 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.36 | 2.35 % | $ 466 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.65 | 1.9 % | $ 3.14 B | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 34.97 | 3.28 % | $ 2.32 B | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 3.37 | -4.4 % | $ 339 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.65 | 2.48 % | $ 439 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | ||
|
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M |